Table 2.
Clinical trials identified at Clinicaltrials.gov related to drug repositioning for COVID-19 treatment.
| Compound | N° test | Clinical condition (sample size of 2019-nCoV participants) | Sponsors | Phase |
|---|---|---|---|---|
| Lopinavir/ritonavir | NCT04321174 | 1220 participants | Darrell Tan | Ⅲ |
| Lopinavir/Ritonavir, Ribavirin and IFN-beta Combination | NCT04276688 | 127 participants | University of Hong Kong, Hospital Authority | Ⅱ |
| Chloroquine Phosphate (CQ) | NCT04328493 | 250 participants | Oxford University Clinical Research Unit, Vietnam | Ⅱ |
| NCT04333628 | 210 participants (Mild) | HaEmek Medical Center, Israel | Ⅱ | |
| hydroxychloroquine (HCQ) | NCT04330144 | 2486 participants | Gangnam Severance Hospital | Ⅲ |
| Azithromycin- Hydroxychloroquine Combination or Hydroxychloroquine | NCT04336332 | 160 participants | Rutgers, The State University of New Jersey | Ⅱ |
| Remdesivir (GS-5734) | NCT04323761 | Expanded Access | Gilead Sciences | – |
| NCT04292899 | 6000 participants (Severe) | Gilead Sciences | Ⅲ | |
| Favipiravir (T-705) | NCT04336904 | 100 participants | Giuliano Rizzardini | Ⅲ |
| NCT04346628 | 120 participants (Mild) | Stanford University | Ⅱ | |
| Baricitinib | NCT04320277 | 200 participants | Hospital of Prato | Ⅱ and Ⅲ |
| NCT04340232 | 80 participants | University of Colorado, Denver | Ⅱ and Ⅲ | |
| Galidesivir (BCX4430) | NCT03891420 | 66 participants | BioCryst Pharmaceuticals | Ⅰ |
| Darunavir and Cobicistat | NCT04252274 | 30 participants | Shanghai Public Health Clinical Center | Ⅲ |
| Hydroxychloroquine, Oseltamivir, or Azithromyci | NCT04338698 | 500 participants | Shehnoor Azhar | Ⅲ |
| CamostatMesylate | NCT04321096 | 580 participants | University of Aarhus | Ⅰ |
| Arbidol (Umifenovir) | NCT04350684 | 40 participants | Shahid Beheshti University of Medical Sciences | Ⅳ |
| NCT04260594 | 380 participants | Jieming QU | Ⅳ |